Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients
Keywords:
COVID-19, SARS-CoV-2, coronavirus infection, hydroxychloroquine, favipiravir, virus eliminationAbstract
The article presents the results of a post-registration observational study to evaluate the results of early initiation of antiviral therapy in patients with COVID-19 receiving treatment at home.
Goal- to evaluate the efficacy and safety of antiviral therapy for the treatment of outpatient patients with coronavirus infection caused by SARS-COV-2.
Materials and methods. The study included 200 outpatient patients with COVID-19. According to etiotropic therapy, patients were divided into 3 groups: those who received favipiravir, hydroxychloroquine and those who did not receive antiviral agents.
Results. The average time to virus elimination while taking favipiravir was 3 (3.0-5.0) days, among those receiving hydroxychloroquine – 5 (4.0-6.0) days, without antiviral therapy – 8.5 (7.0-10.0) days. Normalization of body temperature occurred faster with favipiravir therapy.
Conclusions. Antiviral therapy in outpatient patients with COVID-19 is effective and safe. . Taking favipiravir promotes earlier elimination of the virus, faster normalization of body temperature and a favorable outcome of the disease. Hydroxychloroquine may be prescribed as an alternative antiviral drug to outpatient patients in the absence of a risk of severe course.
Downloads
References
CDC, COVID Data Tracker, Cent. Dis. Control Prev. (2020), (available at https://covid.cdc.gov/covid-data-tracker).
W.H.O. Coronavirus, (COVID-19) Dashboard, (available at https://covid19.who.int).
Wang D, Hu B, Hu C. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323:1061-1069.
Arshad U, Pertinez H, Box H, Tatham L, Rajoki RKR, Curley P, et al. Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775-790. doi: 10.1002/cpt.1909.
Baden LR, Rubin EJ. Covid-19 - The Search for Effective Therapy. N Engl J Med. 2020;382(19):1851-1852. doi: 10.1056/NEJMe2005477.
Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020;40(5):416-437. doi: 10.1002/phar.2398.
Oblokulov A.R., Niyozov G.E. (2020). Clinical and epidemiological characteristics of patients with COVID - 19 International Journal of Pharmaceutical Research, 12 (4), pp. 3749 - 3752.
Oblokulov Abdurashid Raximovich, Jalilova Aziza Sadilloyevna, Mukhtorova Shokhida Abdulloyevna, Raximov Farrux Farxodovich. 2022. Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. 3, 2 (Apr. 2022), 289-294. doi.org/10.17605/OSF.IO/9CFP6.
Oblokulov, A. R., Husenova, Z. Z., & Ergashev, M. M. (2021). Procalcitonin as an indicator of antibacterial therapy in covid-19. Annals of the Romanian Society for Cell Biology, 5220-5224.
Elmurodova A. A. (2022) “Specific Features of the Hemostatic System in Covid-19”. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES 3, 82-85.
Hassaniazad, M, Farshidi, H, Gharibzadeh, A, et al. Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial.J Med Virol. 2022;-8. doi:10.1002/jmv.27724.
Elmurodova A.A., Djalilova A.S., Mukhtorova Sh.A. 2022. Modern Approaches to Treatment of Chronic Giardiasis. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. 3, 2 (Mar. 2022), 102-105.
Abdurashid Rahimovich Oblokulov, Zilola Zohirovna Husenova, Maksudjon Muzaffarovich Ergashev. (2021). Procalcitonin as an Indicator of Antibacterial Therapy in Covid-19. Annals of the Romanian Society for Cell Biology, Volume 25: Issue 3. 5220–5224.
Oblokulov A.R, Elmurodova A.A., Mukhtorova Sh.A, Nurova O.K. (2022). Efficacy and safety of antiviral therapy in patients hospitalized with COVID-19. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES, 3(3), 444-448. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/807
Elmurodova A.A. (2021). Significance of Clinical Symptoms in Assessing the Severity and Prognosis of the Course of Crimean-Congo Hemorrhagic Fever. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES, 35-37. https://doi.org/10.47494/cajmns.vi0.344
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
The work simultaneously licensed under a Creative Commons Attribution 4.0 International License
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
